For Pfizer CEO, two doses of vaccine "offer very limited protection" against Omicron

Albert Bourla, CEO of Pfizer, said in an interview with Yahoo Financethat the anti-Covid vaccine developed by the laboratory was inefficient against the Omicron variant.

“We know that the two doses of the vaccine offer very little or no protection,” said Albert Bourla. “The three doses with a booster offer reasonable protection against hospitalization and death – against death, I think, very good, and less protection against infection,” he however qualified.

A new version of the vaccine specific to Omicron would however be ready by March, doses are already being manufactured. Albert Bourla had also already announced last November that the pharmaceutical company had started the development of this new vaccine.

“We are currently working on a new version of our vaccine, 1.1, if I may put it that way, which will also cover Omicron. Of course, we are waiting for the final results, [mais] the vaccine will be ready in March. ”

In another interview with CNBCAlbert Bourla had said that Pfizer’s new vaccine would also target other variants currently in circulation. “The hope is that we come up with something that will have much, much better protection, especially against infections,” he said while adding: “I don’t know if we will need it, I don’t know. not whether or how it will be used, but we will be ready. “

“Indeed, protection against hospitalizations and serious illness is reasonable right now with current vaccines, as long as you have, say, the third dose.”

Moderna is also working on a new version of its anti-Covid vaccine

On the side of Moderna, its leader Stéphane Bancel also mentioned a booster dose that could be inoculated specifically against the Delta variant by the fall of 2022: “We must be careful to try to stay one step ahead of the virus. , and not stay behind, ”he said in an interview with CNBC.

These new versions of anti-Covid vaccines will, however, have to go through a new phase of approval by the health authorities. A procedure which could be “accelerated” in order to be “adapted” to variants, according to the European Medicines Agency. This new regulatory tool “is specifically [conçu] to allow marketing authorizations [AMM] as quickly as possible, as soon as sufficient data is available ”, according to the EMA quoted by Release.

In March 2021, Ursula von der Leyen had indeed already affirmed the need for “The EMA to accelerate the regulatory approval of suitable vaccines in order to deal with new variants. Faster approval means more vaccines in circulation and more Europeans protected against the virus ”.

Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more